Advertisement
Journal Home
Search for

Volume 193, Issue 3, Pages 331-335 (March 2007)


View previous. 10 of 28 View next.

Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion

Presented at the 49th Annual Meeting of the Midwest Surgical Society, Mackinac Island, MI, August 6–9, 2006

David Yü Greenblatt, M.D., Muthusamy Kunnimalaiyaan, Ph.D., Herbert Chen, M.D., F.A.C.S.Corresponding Author Informationemail address

Received 12 August 2006; received in revised form 20 September 2006

Abstract 

Background

Gastrointestinal carcinoid tumors are highly metastatic. Activation of the Raf-1 signaling pathway in carcinoid cells results in morphologic changes. These Raf-1–induced structural changes may affect cellular adhesion, thereby altering metastatic potential.

Methods

An estrogen-inducible Raf-1 cell line (BON-raf) was used to study the effects of Raf-1 on cellular adhesion. Cell adhesion was measured before and after Raf-1 induction. Western blot analysis was used to confirm Raf-1 activation and measure levels of an essential adhesion regulator, β-catenin.

Results

Estrogen treatment of BON-raf cells resulted in Raf-1 activation and a marked decrease (68%) in cell adhesion. In the absence of Raf-1 induction, carcinoid cells expressed high levels of β-catenin. Raf-1 activation led to decreased expression of β-catenin.

Conclusions

Raf-1 induction in carcinoid cells results in a significant decrease in adhesion. Furthermore, the important adhesion regulator, β-catenin, is decreased in activated BON-raf cells. These Raf-1-related changes in adhesion may alter the metastatic phenotype of carcinoid cells.

Endocrine Surgery Research Laboratories, Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, H4/750 Clinical Science Center, 600 Highland Ave., Madison, WI 53792, USA

Corresponding Author InformationCorresponding author. Tel.: +1-608-263-1387; fax: +1-608-263-7652.

PII: S0002-9610(06)00794-X

doi:10.1016/j.amjsurg.2006.09.016


View previous. 10 of 28 View next.

Advertisement